Maintaining Investments in New Innovation Act
Source: Congress.gov ·
312 words in original text
What This Bill Does
This bill amends the Social Security Act to change the rules for certain drugs that use genetic targeting technology. It extends the protection period for these advanced drugs so pharmaceutical companies get more time before competitors can make similar versions.
Who It Affects
Pharmaceutical companies that develop drugs using genetically targeted technology. Medicare and Medicaid programs that may purchase these drugs.
Key Provisions
• Drugs using genetically targeted technology get 11 years of protection instead of 7 years before generic (lower-cost copy) versions can be made (Sec. 2).
• An "advanced drug product" is defined as a drug that uses or includes genetically targeted technology that can change how a gene functions or change what a gene produces (Sec. 2).
What Changes
The time period protecting certain genetic-based drugs from generic competition increases from 7 years to 11 years.
Important Definitions
Advanced drug product: A drug that uses or includes genetically targeted technology that may change how a gene works or change what a gene produces.
Genetically targeted technology: Not defined in this bill. The bill refers to a definition in another law (Federal Food, Drug, and Cosmetic Act, section 529A(c)(2)).
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.